Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Clinical trial NCT06738368 · RECRUITING
Trial details
- NCT number
- NCT06738368
- Sponsor
- University of Washington
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-08
- Primary completion
- 2028-01-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.